论文部分内容阅读
目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法采用尤瑞克林静脉滴注治疗急性脑梗死患者30例,治疗前、治疗7 d、14 d、治疗结束3个月后观察其临床疗效;用卒中量表评定神经功能缺损程度(NIHSS),Barthel指数量表(BI)评定日常生活活动能力(ADL);检测血常规、尿常规、肝肾功能、凝血、心电图;观察记录不良反应。结果治疗组治疗7 d、14 d、治疗结束3个月后NIHSS评分分别为9.73±5.19、6.93±4.47、6.11±4.23;对照组分别为10.82±6.53、9.74±8.32、8.79±5.01。治疗组治疗7 d、14 d、治疗结束3个月后BI评分分别为58.79±20.54、68.92±12.87、79.59±14.69;对照组分别为45.36±17.61、54.82±18.79、62.99±17.63。结论尤瑞克林治疗急性脑梗死安全、有效,适于临床应用。
Objective To observe the efficacy and safety of urelin in the treatment of acute cerebral infarction. Methods Thirty patients with acute cerebral infarction were treated with intravenous uricase. Before treatment, 7 days and 14 days after treatment, the clinical efficacy was observed 3 months after the end of treatment. The degree of neurological deficit (NIHSS) , Barthel index scale (BI) assessment of daily living activity (ADL); detection of blood, urine, liver and kidney function, coagulation, ECG; observed and recorded adverse reactions. Results The NIHSS scores of the treatment group were 9.73 ± 5.19,6.93 ± 4.47,6.11 ± 4.23 after treatment for 7 days and 14 days, respectively. The control group were 10.82 ± 6.53,9.74 ± 8.32,8.79 ± 5.01 respectively. The scores of BI in the treatment group were 58.79 ± 20.54,68.92 ± 12.87 and 79.59 ± 14.69 after 7 and 14 days of treatment, respectively. The control groups were 45.36 ± 17.61 and 54.82 ± 18.79 and 62.99 ± 17.63 respectively. Conclusion The treatment of acute cerebral infarction with uracil is safe and effective and is suitable for clinical application.